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Introduction {#sec1}
============

ADP-ribosylation (ADPr) is a clinically important posttranslational modification (PTM) that controls many cellular processes, including DNA repair, transcription, translation, and chromatin remodeling ([@bib17], [@bib43], [@bib40], [@bib8]). The ADPr reaction consists of the enzymatic transfer of ADPr from positively charged nicotinamide adenine dinucleotide (NAD^+^) onto an acceptor molecule with the simultaneous release of nicotinamide ([@bib17], [@bib42]). Poly(ADPr) polymerases (PARPs) are the major family of enzymes that perform ADPr, and 17 PARP family members are encoded in the human genome ([@bib2]). PARP1 and PARP2 are the most studied members of the family and are particularly known for their key roles in the DNA damage response (DDR) ([@bib30], [@bib42]).

PARPs modify proteins at specific residues, and several amino acids, most commonly glutamate (Glu) and aspartate (Asp) but also arginine (Arg), lysine (Lys), and cysteine (Cys), have been reported to be ADPr ([@bib51], [@bib50], [@bib11]). Recently, we identified serine ADPr (Ser-ADPr) as an elusive type of histone PTMs that target specific Ser residues ([@bib26]) and revealed the basic molecular mechanisms underlying Ser-ADPr conjugation and its reversal. Specifically, we established Ser as a target of PARP1/2-mediated ADPr ([@bib6]) and described histone PARylation factor 1 (HPF1/C4orf27) as the PARP1/2-interacting protein ([@bib16]) required for conferring specificity toward Ser ([@bib6]). We also characterized ADPr 3 (ARH3, or ADPRHL2) as the hydrolase responsible for Ser-ADPr removal ([@bib15]). Further studies identified hundreds of DNA damage-induced Ser-ADPr sites in proteins involved in DNA repair, transcription, and chromatin organization ([@bib6], [@bib1]) and revealed that Ser-ADPr is the major type of ADPr in the regulation of the DDR ([@bib41]).

Ser-ADPr core histone marks are localized on N-terminal tails ([@bib26]), which are heavily decorated with a plethora of dynamic, covalent modifications, including phosphorylation, acetylation, methylation, and ubiquitylation ([@bib18]). Specific combinations of these marks act together to regulate a host of important nuclear functions, such as chromatin compaction and dynamics, transcription, replication, and DNA repair ([@bib24], [@bib48], [@bib18]). Many studies have already been conducted on various histone modifications, yet all of them have overlooked Ser-ADPr because this PTM remained elusive until recently ([@bib26]). Conversely, despite their focus on histones, studies centered on Ser-ADPr have so far investigated this PTM independent of other histone marks ([@bib26], [@bib6], [@bib15], [@bib4]).

In this paper, we provide insights into the interplay between Ser-ADPr and canonical histone marks. Furthermore, by characterizing the PARP/HPF1-catalyzed ADPr consensus motif, we determine the relative significance of the preceding basic residue and discover tyrosine as an acceptor for ADPr. The resulting interplay analysis examines the effect of surrounding histone PTMs and shows that certain specific acetylation and phosphorylation marks can inhibit Ser-ADPr and vice versa. To broaden and improve studies of histone marks interplay, we introduce a method for visualization of modified as well as unmodified counterpart peptides.

Results {#sec2}
=======

Factors Influencing Ser-ADPr of Histone Peptides {#sec2.1}
------------------------------------------------

To analyze the substrate properties that influence Ser-ADPr, we investigated sequence features that may affect the efficiency of *in vitro* histone peptide ADPr reactions. Our previous proteomics data provided a short consensus motif for *in vivo* Ser-ADPr with either Lys or Arg N-terminal to the target Ser ([@bib26], [@bib6]). Based on these observations, we incubated PARP1 and HPF1 with a variety of histone peptides, each containing an Lys-Ser (KS) motif known to be the modification site *in vivo* ([@bib26]). Similar to what we reported before ([@bib6]), we observed that two different histone H3 peptides as well as H2A and H4 peptides were modified by the HPF1/PARP1 complex *in vitro* ([Figure 1](#fig1){ref-type="fig"}A). The Ser-ADPr glycosylhydrolase ARH3 ([@bib15]) was able to efficiently remove the ADP-ribose on all of the analyzed peptides ([Figure 1](#fig1){ref-type="fig"}A). We also compared the efficiency of H3 peptide 1--20 modification to that of the H3/H4 tetramer and the whole nucleosome. As shown in [Figure S1](#mmc1){ref-type="supplementary-material"}A, peptide modification is not dramatically lower, especially considering the additional ADPr sites on the histone proteins and that this H3 peptide is mostly mono-ADPr *in vitro* ([@bib6]). These experiments establish that KS motifs in a variety of histone peptides can be modified efficiently and reversibly, demonstrating the utility of the histone peptide as a tractable *in vitro* assay for histone Ser-ADPr.Figure 1Modifiers of Serine-ADP-Ribosylation of Histone Peptides(A) Autoradiogram showing ADPr, and subsequent ARH3-mediated glycohydrolysis of H3 1--20aa, H3 27--45aa, H2A 1--17aa, and H4 1--23aa peptides. Coomassie staining of the SDS-PAGE is included and represents the loading control.(B) Autoradiogram showing PARP1/2 + HPF1-mediated ADPr of H3 peptide with Lys9 substituted by Ala and Arg, and Ser10 substituted by Ala. Coomassie staining of the SDS-PAGE is included.(C) 293T cells were transfected with the same amount of empty vector (EV) or plasmid expressing WT, K9A, K9R, or S10A FLAG-tagged histone H3 protein and treated for 10 min with H~2~O~2~. Inputs (A) and FLAG-IPs (B) were analyzed by western blotting.

Next, we opted to focus on H3 Ser10 (H3S10) ADPr, because this site was previously shown to be the primary ADPr site on H3 *in vivo* ([@bib41]). We investigated how alterations of the key KS residues affect the modification profile of the H3 histone peptide *in vitro*. Based on our previous finding that both PARP1 and PARP2 can modify this H3 peptide in the presence of HPF1 ([@bib6]), we examined both PARPs with variations on the KS motif. Substitution of Ser10 with alanine (Ala) led to a complete loss of the modification ([Figure 1](#fig1){ref-type="fig"}B), as we have previously shown ([@bib6]). Changing the neighboring Lys residue into Arg or Ala had varying effects on histone Ser-ADPr. The H3 peptide containing the K9R mutation was still modified, albeit to a lesser extent than wild-type (WT) peptide. In contrast, the H3K9A mutation strongly (but not completely) inhibited histone H3 Ser-ADPr ([Figure 1](#fig1){ref-type="fig"}B), highlighting the importance of a basic residue preceding the Ser. Both PARP1 and PARP2 modified the peptide panel with similar profiles, although PARP1 catalyzed the reactions more efficiently under the conditions used.

We further confirmed the importance of the consensus KS motif for Ser-ADPr *in vivo*. We transfected 293T cells with FLAG-tagged histone H3 WT, K9A, K9R, K9Q, or S10A mutant H3 and assessed ADPr efficiency, as described previously ([@bib41]). DNA damage was induced by the treatment with 2 mM hydrogen peroxide (H~2~O~2~), followed by FLAG-immunoprecipitation (FLAG-IP). Western blotting was performed using a pan-ADPr reagent that recognizes all forms of cellular ADPr ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}B). The ADPr patterns obtained were similar to those observed in our *in vitro* reactions. To note, by using a specific anti-H3K9ac antibody, we show that the KS motif is also important for K9 acetylation *in vivo* ([Figure 1](#fig1){ref-type="fig"}C, FLAG-IP).

These data extend our previous findings that the KS and RS motifs are preferred targets for Ser-ADPr and exclude the possibility that Lys rather than Ser is the modification target.

Discovery of Tyrosine as a Target Residue for ADPr {#sec2.2}
--------------------------------------------------

ADPr of Ser led us to question whether a hydroxyl group is sufficient and necessary to target an amino acid for ADPr when adjacent to Lys. We therefore decided to substitute H3S10 with threonine (Thr) and tyrosine (Tyr), the two other residues that contain hydroxyl groups, and additionally Glu and Asp as further controls. Not only were we unable to detect ADPr on Glu and Asp but also on Thr residues ([Figure 2](#fig2){ref-type="fig"}A). This suggests that although chemically similar to Ser, the additional methyl group on Thr interferes with the ADPr reaction mediated by PARP1/HPF1. In fact, in none of our previous proteomic analyses ([@bib26], [@bib6]) were we able to detect Thr-ADPr. Conversely, we identified a reproducible modification of Tyr when we introduced this amino acid instead of Ser10 ([Figure 2](#fig2){ref-type="fig"}A). Because Tyr has not previously been described as a substrate for ADPr, we sought mass spectrometric evidence for Tyr-ADPr. Although we could not detect Tyr-ADPr in our histone proteomics data ([@bib26]), we confidently identified Tyr-ADPr of HPF1 in an *in vitro* reaction containing PARP1 ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}B). We could also identify Ser97 in HPF1 as another site modified in this reaction ([Figure 2](#fig2){ref-type="fig"}C). These data suggested that PARP1 was the enzyme responsible for HPF1 Tyr-ADPr modification. To follow up on this point, we modified recombinant HPF1 using a panel of different PARPs and radioactively labeled NAD. We could observe a low but reproducible modification by PARP1 and possibly by PARP2 ([Figures 2](#fig2){ref-type="fig"}D, [S2](#mmc1){ref-type="supplementary-material"}A, and S2E). This modification is at least partly dependent on the assembly of the PARP1/HPF1 complex, because the modification of the HPF1 R239A mutant protein (previously shown to be deficient in interacting with PARP; see [@bib16]) was significantly reduced ([Figure 2](#fig2){ref-type="fig"}E).Figure 2Discovery of Tyrosine as a Target Residue for ADPr(A) Autoradiogram showing ADPr of H3 peptide (1--20aa) with Ser10 substituted by Ala, Thr, Tyr, Glu, and Asp, alongside Lys9 substituted by Arg and Ala. Coomassie staining of the SDS-PAGE is included.(B) High-resolution ETD fragmentation spectrum of an HPF1 peptide modified by ADP-ribose on tyrosine 238. The chemical structure of ADP-ribose is depicted (see also [Figure S2](#mmc1){ref-type="supplementary-material"}B). ^∗^1, peaks corresponding to co-isolated species in their original charge state. Multiple species in charge states 2--5 passed through the quadrupole and could not be completely deconvoluted.(C) High-resolution ETD fragmentation spectrum of an HPF1 peptide modified by ADP-ribose on serine 97. The chemical structure of ADP-ribose is depicted.(D) Autoradiogram showing a panel of PARPs incubated with HPF1 protein. Reaction with mono(ADP-ribosyl)ating PARP1 E988Q (EQ) mutant enhances detection of the HPF1 ADPr. Coomassie staining of the SDS-PAGE is included.(E) Autoradiogram showing PARP1 E988Q-mediated ADPr of HPF1 WT, HPF1 R239A, and GST-HPF1 proteins. Coomassie staining of the SDS-PAGE is included.(F) 293T cells were transfected with the same amount of EV or plasmid expressing WT, S97A, or Y238A FLAG-tagged HPF1 protein and left untreated or treated for 10 or 120 min with H~2~O~2~. Inputs and FLAG-IPs were analyzed by western blotting. CMV, cytomegalovirus.(G) 293T parental or PARP1 KO cells were transfected with the same amount of EV or plasmid expressing WT FLAG-tagged HPF1 protein and left untreated or treated for 10 or 120 min with H~2~O~2~. Inputs and FLAG-IPs were analyzed by western blotting.

To confirm the ADPr of HPF1 *in vivo*, we overexpressed and immunoprecipitated FLAG-tagged HPF1 WT, S97A, and Y238A mutant proteins from 293T cells, as was described above for histone H3. We observed that HPF1 is significantly modified in cells even in undamaged conditions ([Figure 2](#fig2){ref-type="fig"}F). We did not detect a major effect of the S97A mutation on the modification of HPF1. However, mutation of the Tyr238 site to Ala had a profound effect on the HPF1 ADPr signal ([Figure 2](#fig2){ref-type="fig"}F). This defect may be at least partly due to a reduced ability of the Y238A mutant to interact with PARP1 and to stimulate ADPr ([@bib16]). To further prove that HPF1 ADPr is dependent on PARP1, we performed FLAG-IP in PARP1 knockout (KO) 293T cells. As can be seen in [Figure 2](#fig2){ref-type="fig"}G, HPF1 ADPr is largely missing in PARP1 KO cells. It is likely that the remaining HPF1 modification is due to PARP2 activity. ADPribosylation of Tyr238 is not essential for the global HPF1-dependent ADPr of histones because the non-modifiable Y238F HPF1 mutant supports this activity both in cells and *in vitro* ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B).

While it appears that there may be multiple ADPr sites on HPF1, we were able to confirm the ADPr of Y238 on HPF1 in cell extracts by ADPr mapping through reprocessing ([@bib31]) of a published dataset ([@bib4]) ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Reanalysis of a large-scale ADPr dataset ([@bib29]) revealed four additional high-certainty Tyr-ADPr target proteins ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2E--S2G). Although the type of mass spectrometric analysis used to generate the latter dataset is suboptimal (for additional information about the inadequacies of the higher-energy collisional dissociation \[HCD\] technology for ADPr site mapping, please refer to [@bib5]), our discovery of a Tyr-ADPr diagnostic peak ([Figure S2](#mmc1){ref-type="supplementary-material"}C) enhances the confidence of Tyr-ADPr site mapping.

Canonical H3 Histone Marks Reduce the Efficiency of H3S10ADPr on H3 Peptide {#sec2.3}
---------------------------------------------------------------------------

We observed that removal of the positively charged Lys through the synthesis of an H3 peptide containing an Ala in position 9 instead of an Lys almost completely abolished Ser-ADPr ([Figures 1](#fig1){ref-type="fig"}B and 1C). It is known that acetylation neutralizes the positive charge of Lys residues, whereas methylation maintains the charge. Thus, the presence of this frequently modified residue in our consensus motif led us to hypothesize that modifications of the Lys preceding the Ser may have different effects on Ser-ADPr, a potential mechanism of interplay between the known histone modifications in the H3S10 environment and H3S10ADPr. Additionally, the recent evidence of PARPs conjugating ADPr to phosphorylated DNA ([@bib47], [@bib37]) raised the intriguing possibility of PARPs ADPr a phosphorylated peptide---H3S10ph in this case. Because these endogenous histone PTMs (histone marks) are highly dynamic in cells and organisms, an interplay is likely to have important biological consequences. By examining "marked" histone peptides *in vitro*, we can generate "snapshots" of this dynamic interplay.

We therefore set out to investigate the effect on H3S10ADPr of the histone mark environment around H3S10, which is a particularly PTM-rich and biologically important histone region ([@bib18]). H3K9ac severely inhibits histone H3S10ADPr ([Figure 3](#fig3){ref-type="fig"}A), as also shown in a recent report ([@bib28]), and reversal of Lys9 acetylation by using deacetylase enzymes (HDAC2, SIRT2) re-established this peptide as a substrate for Ser-ADPr by PARP1/HPF1 ([Figure S4](#mmc1){ref-type="supplementary-material"}A). In comparison, H3K9me1 causes only a very mild reduction of H3S10ADPr levels compared to the unmodified peptide. Phosphorylation of the target residue, Ser10, completely blocked ADPr of the peptide, confirming that ADPr and phosphorylation of the Ser10 site are mutually exclusive ([Figure 3](#fig3){ref-type="fig"}A). In agreement with this, we did not find any mass spectrometric evidence for ADPr of a phosphorylated Ser. This indicates that PARP1-mediated ADPr of DNA on a phosphate group ([@bib47], [@bib37]) is mechanistically different from HPF1-dependent ADPr by PARP1 on protein substrates.Figure 3Canonical H3 Histone Marks Reduce the Efficiency of H3S10ADPr on H3 Peptide(A) Autoradiogram showing PARP1/2 + HPF1-mediated ADPr of H3 peptide with WT, K9ac, K9me1, and S10ph modifications. Coomassie staining of the SDS-PAGE is included.(B) As in (A), except PARP1 and HPF1 only, with H3 (1--20aa) WT, K9ac, K9me1, K9me2, and K9me3 peptides. Coomassie staining of the SDS-PAGE is included.(C) As in (B), except with H3 (1--20aa) WT, K4ac, K4me3, K9ac, K9me1, K9me3, S10ph, K14ac, K18ac, and K18me3 peptides. Coomassie staining of the SDS-PAGE is included.(D) As in (B), except with H3 (21--44aa) WT, K27ac, K27me1, K27me2, K27me3, and WT peptides. Coomassie staining of the SDS-PAGE is included.

Given that H3K9me1 did not notably compromise S10ADPr levels, we analyzed whether dimethylations or trimethylations, both commonly observed in the histone code, would have a greater impact on the reaction. We noted a stepwise decrease in H3S10ADPr levels on H3K9me1, H3K9me2, and H3K9me3 substrates, with H3K9me3 permitting only a very modest degree of PARP1/HPF1-dependent H3S10ADPr ([Figure 3](#fig3){ref-type="fig"}B). Because H3K9me and H3S10ADPr modifications could coexist on the H3 peptide, we investigated whether the recently identified enzyme that removes Ser-ADPr, ARH3, could still access and remove H3S10ADPr in the presence of H3K9me. Our analysis showed that ARH3 was still active against H3S10ADPr, irrespective of the H3K9me marks, and could efficiently erase H3S10ADPr signals from modified H3 peptides ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

To investigate the effect of known histone marks in a wider context, we broadened the scope of our analysis of residues surrounding H3S10ADPr by testing H3K4ac, H3K4me3, H3K14ac, H3K18ac, and H3K18me3 peptides. Of these additional histone marks, only H3K14ac notably affected the subsequent addition of ADPr to H3S10 ([Figure 3](#fig3){ref-type="fig"}C).

Because our earlier experiments had determined that H4 1--23 and H3 27--45 peptides were suitable for PARP1/HPF1-dependent Ser-ADPr modification, we tested both for crosstalk between nearby acetylation and methylation modifications with H4S1ADPr and H3S28ADPr. We found that the modification of the KS motif at S28 has effects similar to those seen for Ser10 ([Figure 3](#fig3){ref-type="fig"}D). Alternatively, H3K36me1, H3K36me2, or H3K36me3 did not reduce the H3S28ADPr modification signals, while the H3K36ac had only a modest effect ([Figure S4](#mmc1){ref-type="supplementary-material"}C). We also found that none of the H4R3me2, H4K5ac, or H4K8ac marks had a discernible effect on H4S1ADPr levels compared to the unmodified peptide ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

Ser-ADPr on H3S10 Prevents the Efficient Incorporation of H3K9 Acetylation and H3S10 Phosphorylation {#sec2.4}
----------------------------------------------------------------------------------------------------

We conducted reciprocal experiments based on our above findings, this time modifying histone H3 peptide first with PARP1/HPF1 complex ([Figure S5](#mmc1){ref-type="supplementary-material"}), then subsequently incubating the reaction products in acetylation, phosphorylation, and methylation reaction mixtures using the purified catalytic domain of p300, the activated fragment of Aurora B kinase (Baronase; to phosphorylate H3S10) and Dim5 methyltransferase ([@bib38], [@bib36], [@bib53]). We detected the acetylated products of Ser-ADPr H3 peptides using a specific H3K9ac antibody and observed that K9ac is effectively prevented if the peptide is previously ADPr ([Figure 4](#fig4){ref-type="fig"}A, lane 5). To control for any possible interference of ADPr with western blot detection, we incubated the Ser-ADPr H3 peptide with p300, stopped the reaction, and removed Ser-ADPr from the peptide using ARH3. This assay showed only a negligible amount of H3K9Ac ([Figure 4](#fig4){ref-type="fig"}A, lane 6). In a similar experiment, we saw that Ser-ADPr of H3 peptide prevented subsequent H3S10 phosphorylation ([Figure 4](#fig4){ref-type="fig"}B, lane 5). Finally, we incubated an Ser-ADPr H3 peptide in an Lys methylation reaction and found that H3S10ADPr did not preclude the incorporation of H3K9me3, although it did substantially reduce the efficiency of the reaction compared to the unmodified H3 peptide ([Figure 4](#fig4){ref-type="fig"}C, lane 3 versus lane 5).Figure 4H3S10ADPr Reduces the Efficiency of Subsequent H3K9 Acetylation and H3S10 Phosphorylation(A) Western blot showing PARP1/HPF1 ADPr of H3 (1--20aa) peptide and subsequent p300-mediated acetylation. One reaction was stopped after p300 incubation, then supplemented with ARH3 to remove ADPr before signal detection. Membrane probed with H3K9ac antibody, with H3K9ac peptide included as a positive marker.(B) Western blot showing PARP1/HPF1 ADPr of H3 (1--20aa) peptide and subsequent Baronase-mediated phosphorylation. Control sample excludes NAD from the PARP1/HPF1 reaction. Membrane probed with H3S10ph antibody, with H3S10ph peptide included as a positive marker.(C) Western blot showing PARP1/HPF1 ADPr of H3 (1--20aa) peptide and subsequent Dim5-mediated methylation. Control sample excludes NAD from the PARP1/HPF1 reaction. Membrane probed with H3K9me3 antibody, with H3K9me3 peptide included as a positive marker.

An Approach for Rapid and Easy Analysis of ADPr Peptides {#sec2.5}
--------------------------------------------------------

Our approaches above use \[^32^P\]NAD as a detection method, but this radioactive technique is expensive and requires strict safety procedures. Furthermore, using \[^32^P\]NAD and standard gel electrophoresis only allows the detection of modified product, rather than an analysis of unmodified and modified peptides together (i.e., substrates and products). These limitations, together with the clear importance of studying the interplay of Ser-ADPr and other known histone marks, motivated us to look for a simpler approach that could be implemented in virtually any biological laboratory. Given that ADP-ribose is a nucleotide, we reasoned that an electrophoresis system capable of resolving a one-nucleotide difference in the length of oligonucleotides would allow a clear separation of ADPr and unmodified substrate peptides. However, the negatively charged nucleic acids are separated by migrating toward the positively charged anode. In contrast, the histone tail peptides have a net positive charge, even when modified by ADP-ribose and would therefore migrate in the wrong direction. By changing the polarity of the electrodes, the positively charged substrate peptides can be driven into gels intended for electrophoresis of short nucleic acids and be separated according to their charge. Following ADPr, peptides become less positively charged and therefore migrate more slowly, which allows a clear spatial separation between the bands of the modified and unmodified peptides ([Figure 5](#fig5){ref-type="fig"}A). After the run, both species (unmodified and modified) can be clearly visualized and quantified by Coomassie-based staining, which reveals by band shift how much of the starting peptide has been ADPr ([Figure 5](#fig5){ref-type="fig"}A). [Figure 5](#fig5){ref-type="fig"}B shows an exemplar of this technique, comparing unmodified H3 peptide during a time course with PARP1, HPF1, and H3 peptide, with the modified peptide shifted upward at later time points. Incubating modified H3 peptide with ARH3 reverses the band shift to the unmodified state ([Figure 5](#fig5){ref-type="fig"}C). We then expanded this method to investigate ADPr efficiency on H3 peptides with a variety of histone marks. We observed that H3K4me mildly reduced ADPr levels compared to WT, whereas H3R8me peptides were modified efficiently ([Figure 5](#fig5){ref-type="fig"}D). H3K9ac, H3K9me, and K14ac modification profiles were comparable to the \[^32^P\]NAD experiments, reinforcing the value of this Coomassie-based approach for estimating the efficiency of a reaction. Additionally, we examined an H3T11ph peptide, which showed only a very slight ADPr band, suggesting a strong inhibition of HPF1/PARP1-catalyzed Ser-ADPr by the adjacent phosphorylation ([Figure 5](#fig5){ref-type="fig"}D). These combined experiments produced a map of the histone marks within a local region around H3S10 that affect the efficiency of H3S10ADPr ([Figure 5](#fig5){ref-type="fig"}E). Notably, histone marks other than ADPr also generated a band shift compared to the unmodified counterpart peptide ([Figure 5](#fig5){ref-type="fig"}D, left). This implies that the utility of our approach is not limited to ADPr and that this technique can be used to study the dynamics of other histone marks at the peptide level, such as the interplay between phosphorylation and acetylation ([@bib23]).Figure 5A Technique to Rapidly Analyze ADP-Ribosylated Peptides(A) Schematic representation of the approach to rapidly and easily analyze the modification status of positively charged histone tail peptides.(B) Imperial stained gel showing ADPr of H3 (1--21aa) peptides after addition of PARP1/HPF1 during a 6-hr time course. The upward band shift denotes ADPr of the H3 peptide.(C) Imperial stained gel showing ADPr of H3 (1--21aa) peptides after addition of PARP1/HPF1 and subsequent addition of ARH3. The upward band shift denotes ADPr of the H3 peptide.(D) Imperial stained gel showing H3 (1--21aa) WT, K4me1, K4me2, K4me3, R8me1, R8me2a, K9ac, K9me1, K9me2, K9me3, S10ph, T11ph, and K14ac peptides and subsequent ADPr following addition of PARP1 and HPF1. The upward band shift denotes ADPr of the H3 peptide.(E) A schematic showing a map of histone H3 1--20aa with histone marks that interfere with Ser-ADPr on H3 peptide *in vitro*.

H3K9ac and S10ADPr Are Mutually Exclusive Histone Marks in Human Cells {#sec2.6}
----------------------------------------------------------------------

We sought to assess whether the results generated using histone H3 peptides could be replicated with intact human nucleosomes *in vitro*. WT and H3K9ac recombinant human mononucleosomes were incubated with PARP1 in the presence and absence of HPF1. We observed a clear contrast between the WT and H3K9ac nucleosomes when incubated with PARP1/HPF1, with WT displaying a higher level of Ser-ADPr ([Figure 6](#fig6){ref-type="fig"}A). The H3K9ac nucleosomes were still significantly modified, albeit to a lower degree, presumably due to modifications of other previously observed histone tail sites, such as H3S28 and H2BS6 ([@bib26]). Similarly, we performed an assay using a nucleosome substrate to test the reciprocal reactions, namely Ser-ADPr, and then acetylation of the nucleosome ([Figure 6](#fig6){ref-type="fig"}B). We saw that prior Ser-ADPr reduced subsequent H3K9 acetylation, as detected by the specific anti-H3K9ac antibody ([Figure 6](#fig6){ref-type="fig"}B). These results suggest that the interplay that we observe between Ser-ADPr and acetylation of neighboring Lys residues on the peptide level also occurs in the context of whole nucleosomes and *in vivo*. We also observed that prior H3S10 phosphorylation of the nucleosome also significantly reduced subsequent p300-mediated acetylation of H3K9 ([Figure 6](#fig6){ref-type="fig"}B).Figure 6H3K9ac and S10ADPr Are Mutually Exclusive Histone Marks in Human Cells(A) Autoradiogram showing PARP1 mediated ADPr in the presence of absence of HPF1, with either WT or K9ac human recombinant nucleosomes. Coomassie staining of the SDS-PAGE is included.(B) Western blot showing PARP1/HPF1 ADPr of recombinant human nucleosome and subsequent p300-mediated acetylation. One reaction includes Baronase incubation instead of ADPr reaction, before p300 acetylation reaction. Membrane probed with H3K9ac antibody, with commercially obtained recombinant human H3K9ac nucleosome included as a positive marker.(C) High-resolution ETD fragmentation spectrum of a H3 peptide modified by methyl on lysine 9 and ADP-ribose on serine 10 obtained from [@bib26]. The chemical structure of methyl and ADP-ribose are depicted.(D) High-resolution ETD fragmentation spectrum of a H3 peptide modified by acetylation on lysine 9 and lysine 14 obtained from [@bib26]. The chemical structure of acetylation is depicted. ^∗^1, Peak corresponding to an unfragmented co-eluting, co-isolated +2 precursor deconvoluted into the +1 state. ^∗^2, Peak corresponding to an unfragmented co-eluting, co-isolated +3 precursor deconvoluted into the +1 state.(E) Schematic summary of canonical histone H3 marks and their interactions with Ser-ADPr based on the mass spectrometry (MS) analysis of U2OS cell extracts from [@bib26]. The marks depicted on the top are H3 marks that can coexist with Ser10 or Ser28 ADPr *in vivo*, while the H3 marks depicted on the bottom are mutually exclusive with ADPr on Ser10 or Ser28.

To compare the interplay observed in our *in vitro* system with that in cells, we analyzed U2OS cell extracts by high-resolution electron-transfer dissociation (ETD) mass spectrometry ([@bib26]). We identified H3S10ADPr in the presence of mono-, di-, and trimethylation of H3K9 and with H3K14ac, but never with H3K9ac ([Figures 6](#fig6){ref-type="fig"}C and [S6](#mmc1){ref-type="supplementary-material"}A--S6C). Any detection of H3K9ac was in the absence of H3S10ADPr, although we were able to detect H3K9ac in co-existence with marks other than H3S10ADPr, such as H3K14ac ([Figure 6](#fig6){ref-type="fig"}D). To test whether our failure to detect H3K9ac and H3S10ADPr together was due to technical limitations, we purified small amounts of H3K9acS10ADPr peptide generated from a highly inefficient reaction and analyzed it by mass spectrometry. We found that we were able to detect both histone marks on the same peptide ([Figure S6](#mmc1){ref-type="supplementary-material"}D), further indicating that the apparent non-coexistence of these marks is due to the mutual exclusivity *in vivo* rather than our technical inability of detecting doubly modified H3K9ac/H3S10ADPr peptides. Our findings define two groups of histone H3 PTMs that can either coexist with or are mutually exclusive to Ser-ADPr ([Figure 6](#fig6){ref-type="fig"}E).

To further characterize the interplay between histone Ser-ADPr and other PTMs *in vivo*, we assessed the levels of H3S10ph, H3K9ac, H3K9me3, and several other PTMs around the H3S10ADPr site in 293T cells following DNA damage ([Figure 7](#fig7){ref-type="fig"}A). Our results confirmed previously published data showing reduction of H3K9ac in response to DNA damage ([@bib49]), because we also observed striking specific deacetylation of the H3K9 site after 120 min of treatment ([Figure 7](#fig7){ref-type="fig"}A). We also observed significant deacetylation of H3K14 under the same conditions ([Figure 7](#fig7){ref-type="fig"}A). DNA damage-induced deacetylation of both H3K9 and H3K14 was completely blocked by pre-treatment with a PARP inhibitor, olaparib. We did not observe DNA damage-induced deacetylation of H3K27ac or K36ac, or demethylation of H3K9me3 or H3K27me3, among others ([Figure 7](#fig7){ref-type="fig"}A). As evident from the patterns for the cell-cycle proteins cyclin A, B1, E1, Cdc2 T15P, PRC1 T481P, and p21 ([Figure 7](#fig7){ref-type="fig"}A), the cell cycle was unaffected by olaparib treatment in our experimental settings.Figure 7Histone Mark Response to DNA Damage with PARP Inhibition and Persistent Ser-ADPr(A) 293T cells were pretreated with DMSO or olaparib and treated with H~2~O~2~. Western blotting analysis of the changes in histone H3 K9ac, K9me3, S10P, K14ac, K27ac, K27me3, and K36ac, as well as total pan-Kac histone acetylation and cell-cycle protein levels was performed at the indicated times after the induction of DNA damage.(B) U2OS WT and ARH3 KO cells were treated with H~2~O~2~. The levels of H3K9ac, H3K9me3, and pan-Kac were examined by western blotting at the indicated time points.

To test our hypothesis that Ser-ADPr specifically affects these canonical histone marks, we performed similar experiments in ARH3 KO cells. We have previously demonstrated that these cells have chronically increased histone ADPr, including the Ser10 site ([@bib15], [@bib41]). DNA damage-induced deacetylation was more robust in these cells, which was especially obvious at 10 and 120 min post-DNA damage ([Figure 7](#fig7){ref-type="fig"}B). It is worth mentioning that some other acetylated proteins, detected by pan-acetylation antibody, displayed a different profile of increasing acetylation after DNA damage treatment ([Figure 7](#fig7){ref-type="fig"}B). These results combined suggest that interplay between histone ADPr and K9 acetylation and some other forms of histone modifications takes place in living cells. This knowledge can offer a framework for the further investigation of crosstalk between Ser-ADPr and other histone marks, and onward toward a wider understanding of the physiological function of Ser-ADPr as a histone mark and as a PTM.

Discussion {#sec3}
==========

Ser-ADPr is a recent addition to the array of PTMs found on mammalian proteins ([@bib26]), and several studies have started to delineate its physiological relevance ([@bib15], [@bib6], [@bib41]). Ser-ADPr is found on a large number of proteins ([@bib26], [@bib1], [@bib6]), and Ser is the primary amino acid acceptor residue of ADPr following DNA damage in human cells ([@bib41]). Histone proteins are subject to a large variety of PTMs, many of which are directly involved in the regulation of chromatin structure and transcription and play important roles in DNA replication and repair ([@bib24]). This raises the question as to how Ser-ADPr functions in this densely modified environment and how the other histone marks affect the DDR as a consequence of their crosstalk with Ser-ADPr.

Our findings demonstrate the interplay between Ser-ADPr and a number of canonical histone marks, also showing that the process of Ser-ADPr is dependent on the context of the local histone code and vice versa. Whereas most of the histone Ser-ADPr sites examined in this work have previously been reported to be phosphorylated under certain conditions ([@bib18], [@bib26]), ADPr of H3S10 and H3S28 are particularly intriguing, because H3S10ph and H3S28ph were suggested to play key roles in mitosis ([@bib46], [@bib24]). Moreover, acetylation of H3K9 and H3K27, which are mutually exclusive of ADPr at H3S10 and H3S28, respectively, is critical in the regulation of gene expression ([@bib24]). This suggests that the prior modification of H3K9 and H3K27 could prevent the expansion of the Ser-ADPr signal or that, following DNA damage, neither H3K9ac/H3K27ac nor H3S10ph/H3S28ph marks would be "permitted" to initiate their responses. Because H3K9ac is frequently associated with transcriptionally active areas ([@bib24]), it is logical that in the event of DNA damage, it would be undesirable to collect a large body of repair factors while the transcription machinery is still local and active. Accordingly, in response to DNA damage, H3K9Ac becomes diminished at promoter regions of cell-cycle-responsive and active gene sites and at the sites of DNA lesions ([@bib49], [@bib3], [@bib33]). Here, we also showed that H3K9ac decreases following H~2~O~2~ treatment in human cells. The levels of H3K14ac changed in a manner similar to H3K9ac, and K14 acetylation on H3 peptide also blocks H3S10ADPr *in vitro*. Given that H3K9ac and H3K14ac marks have already been shown to have similar patterns and roles in the recruitment of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex and spreading of γH2AX ([@bib25]), it is not surprising that transient K14ac deacetylation could also be important for efficient DDR.

Notably, we confirmed previous findings that H3S10ph decreases after DNA damage treatment ([@bib35]), even more sharply than does H3K9ac, suggesting the importance of H3S10 dephosphorylation in DDR. Both DNA damage-induced H3K9 deacetylation and H3S10 dephosphorylation were prevented by treatment with the clinically approved PARP inhibitor olaparib, suggesting that both marks have a strict interplay with PARP1/2 activity. The inhibitory effect of olaparib on H3S10 dephosphorylation was already observed ([@bib35]). Because H3S10ph is correlated with transcriptional activation, mitosis, and meiosis ([@bib24]), it is plausible that DDR-related histone marks could be a detrimental addition during some steps of the cell cycle or in some DNA repair pathways.

Alternatively, the methylation of H3K9 and H3K27, both of which are associated with transcriptional repression ([@bib24], [@bib55]), do not prevent the ADPr of the neighboring Ser sites. In concordance, we showed that cellular H3K9me3 levels remain stable after DNA damage, which was also previously reported ([@bib49]).

Although we did not see the effects of H3K36me2 in our systems, this PTM was previously identified as a DNA damage mark that facilitates the recruitment of DNA repair proteins and is crucial for efficient repair ([@bib14]). Changes in many other histone modifications have also been described during the DDR. Of note, PARP1 can change PTM landscapes, not only by means of ADPr but also indirectly by modulating the activity of chromatin remodelers and histone-modifying enzymes ([@bib17]). According to our results, not all of the histone marks are involved in the interplay with Ser-ADPr following a certain DNA damage stimulus. However, these histone marks may be involved in response to other agents and/or in control of different DNA repair pathways. Nevertheless, it is tempting to speculate that it is the specific combination of many histone PTMs that defines the exact molecular pathway that the cell will follow to attempt DNA repair.

The inhibitory effect of histone acetylation on Ser-ADPr could explain why combining PARP inhibitors (PARPis) with histone deacetylase inhibitors (HDACis) results in increased DNA damage and cellular sensitivity ([@bib34], [@bib7], [@bib45], [@bib20], [@bib54], [@bib19]). While both PARPis and HDACis are already individually in clinical trials, our data showing that DNA damage-induced K9 deacetylation is blocked by PARPis further strengthen the pre-clinical rationale for their simultaneous administration. At the same time, future investigation of the effects of including HDACis into the known combination therapies involving PARPis ([@bib12]) could highlight other promising therapeutic strategies.

The field of Ser-ADPr has developed rapidly due to advances in proteomics methods to overcome longstanding technical challenges associated with unbiased ADPr mapping ([@bib26], [@bib5], [@bib6]). Beyond Ser-ADPr site identification, future efforts will be directed toward understanding the functional consequences of Ser-ADPr and the detailed molecular mechanisms. ADPr differs among the well-studied PTMs for its lack of experimental tools and techniques needed for progress in the field. This is beginning to change ([@bib11]), and to facilitate the investigation of Ser-ADPr, we have also developed approaches that can be readily adopted by the majority of biological laboratories ([@bib15], [@bib41]). Here, we have also introduced a method to dramatically simplify and improve the detection of Ser-ADPr peptides. This strategy overcomes the limitations of traditional radioactive techniques and allows an estimation of the extent of modification, which is impossible with other available techniques. Thus, our approach will clearly facilitate investigations of the dynamics of canonical histone marks, such as phosphorylation and acetylation.

We have demonstrated that Ser-ADPr is a histone mark that is mutually exclusive with neighboring acetylation and phosphorylation both *in vitro* and *in vivo*. Further characterizing the interplay between Ser-ADPr and the PTMs of histone residues ([@bib28]) and of other proteins is of great interest and will provide valuable insights into the complex crosstalk regulating the architecture and accessibility of chromatin. Given the conservation of the KS motifs in Ser-ADPr for hundreds of proteins, acetylation and phosphorylation of the KS motifs could likely be a general strategy to regulate ADPr of proteins involved in genome stability beyond histones.

This study and the tools we have developed have also led to the discovery of Tyr-ADPr (also noted recently by [@bib27]). As with the recent discovery of Ser-ADPr, this initial finding poses a tantalizing number of questions. While we show that PARP1/HPF1 is able to catalyze Tyr-ADPr, are there other writers of this modification? What are enzymes that remove Tyr-ADPr? How common is this modification and what is the physiological relevance? The HPF1 Tyr-ADPr site (Tyr238) constitutes the main PARP1-binding residue ([@bib16]), and substitution of Tyr238 (along with Arg239) to Ala prevents PARP1/HPF1 interaction. These data suggest that Tyr238 modification could be a secondary level of regulation for the stability and activity of the PARP1/HPF1 complex. In this context, our discovery of a Tyr-ADPr diagnostic peak will enhance future proteomics identifications of Tyr-ADPr sites and understanding of their physiological relevance. In summary, our study provides insights into the interplay of Ser-ADPr and other histone marks and provides evidence for an intriguing type of ADPr.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Chemicals, Peptides, and Recombinant Proteins**Recombinant human mononucleosomesEpiCypherCat\# 16-0006Recombinant human mononucleosomes H3 K9acEpiCypherCat\# 16-0314Activated DNATrevigenCat\# 4671-096-06NAD+TrevigenCat\# 4684-096-0232P-NAD+Hartmann AnalyticCat\# ARP 0141Histone H3 (1 - 21), BiotinylatedAnaSpecCat\# AS-61702Histone H3K4me (1 - 21), BiotinylatedAnaSpecCat\# AS-64355Histone H3K4me2 (1 - 21), BiotinylatedAnaSpecCat\# AS-64356Histone H3K4me3 (1 - 21), BiotinylatedAnaSpecCat\# AS-64357Histone H3R8me (1 - 21), BiotinylatedAnaSpecCat\# AS-64607Histone H3R8me2 (1 - 21), BiotinylatedAnaSpecCat\# AS-64972Histone H3R8me2 (1 - 21), BiotinylatedAnaSpecCat\# AS-64972Histone H3K9ac (1 - 21), BiotinylatedAnaSpecCat\# AS-64361Histone H3K9me (1 - 21), BiotinylatedAnaSpecCat\# AS-64358Histone H3K9me2 (1 - 21), BiotinylatedAnaSpecCat\# AS-64359Histone H3K9me3 (1 - 21), BiotinylatedAnaSpecCat\# AS-64360Histone H3S10ph (1 - 21), BiotinylatedAnaSpecCat\# AS-64611Histone H3T11ph (1 - 21), BiotinylatedAnaSpecCat\# AS-64973Histone H3K14ac (1 - 21), BiotinylatedAnaSpecCat\# AS-64362Histone H3 peptide 1-20aa, biotinylatedEpiCypherCat\# 12-0001Recombinant human PARP1 protein[@bib21]N/ARecombinant human PARP2 protein[@bib22]N/AHistone H3 peptide K4ac 1-20aa, biotinylatedEpiCypherCat\# 12-0002Histone H3 peptide K14ac 1-20aa, biotinylatedEpiCypherCat\# 12-0004Histone H3 peptide K18ac 1-20aa, biotinylatedEpiCypherCat\# 12-0005Histone H3 peptide K4me3 1-20aa, biotinylatedEpiCypherCat\# 12-0009Histone H3 peptide K18me3 1-20aa, biotinylatedEpiCypherCat\# 12-0015Histone H3 peptide K9ac 1-20aa, biotinylatedEpiCypherCat\# 12-0003Histone H3 peptide K9me1 1-20aa, biotinylatedEpiCypherCat\# 12-0010Histone H3 peptide K9me2 1-20aa, biotinylatedEpiCypherCat\# 12-0011Histone H3 peptide K9me3 1-20aa, biotinylatedEpiCypherCat\# 12-0012Histone H3 peptide S10ph 1-20aa, biotinylatedEpiCypherCat\# 12-0041Histone H3 peptide 15-34aa, biotinylatedEpiCypherCat\# 12-0016Histone H3 peptide 27-45aa, biotinylatedEpiCypherCat\# 12-0020Histone H4 peptide 1-23aa, biotinylatedEpiCypherCat\# 12-0029Histone H4 peptide K5ac 1-23aa, biotinylatedEpiCypherCat\# 12-0030Histone H4 peptide K8ac 1-23aa, biotinylatedEpiCypherCat\# 12-0031Histone H4 peptide R3me 1-23aa, biotinylatedEpiCypherCat\# 12-0059Histone H2A peptide 1-17aa, biotinylatedEpiCypherCat\# 12-0112Histone H3 peptide K36ac 27-45aa, biotinylatedEpiCypherCat\# 12-0129Histone H3 peptide K36me1 27-45aa, biotinylatedEpiCypherCat\# 12-0174Histone H3 peptide K36me2 27-45aa, biotinylatedEpiCypherCat\# 12-0115Histone H3 peptide K36me3 27-45aa, biotinylatedEpiCypherCat\# 12-0212Recombinant human HPF1 protein[@bib16]N/ARecombinant human HPF1 Y238F proteinThis paperN/ARecombinant human HPF1 Y238A proteinThis paperN/ARecombinant human HPF1 Y238E proteinThis paperN/ARecombinant human ARH3 protein[@bib15]N/AImperial Protein StainThermofisher ScientificCat\# 24615OlaparibCayman ChemicalCat\# 10621Histone H3 (21-44), BiotinylatedAnaSpecCat\# AS-64641Histone H3K27ac (21-44), BiotinylatedAnaSpecCat\# AS-64637Histone H3 (21-44), BiotinylatedAnaSpecCat\# AS-64440Histone H3K27me1 (21-44), BiotinylatedAnaSpecCat\# AS-64365Histone H3K27me2 (21-44), BiotinylatedAnaSpecCat\# AS-64366Histone H3K27me3 (21-44), BiotinylatedAnaSpecCat\# AS-64367Histone H3/H4 tetramer[@bib32]N/Ap300, human, recombinant, catalytic domainEnzo Life SciencesCat\# BML-SE451-0100Dim-5, recombinant, Neurospora crassa[@bib52]N/ABaronaseGift from Francis Barr (University of Oxford)N/APARP3, human, recombinant[@bib6]N/APARP10 catalytic domain, human, recombinant[@bib39]N/ARecombinant human PARP1 E988Q protein[@bib21]N/AHDAC2, human recombinantActive MotifCat\# 31505SIRT2, human, recombinant[@bib44]N/A**Antibodies**anti-pan-ADP-ribose (rabbit monoclonal)MilliporeCat\# MABE1016; RRID:[AB_2665466](nif-antibody:AB_2665466){#intref0010}anti-PAR (rabbit polyclonal)TrevigenCat\# 4336-BPC-100; RRID:[AB_2721257](nif-antibody:AB_2721257){#intref0015}anti-Flag HRP-conjugated (mouse monoclonal)Sigma-AldrichCat\# A8592; RRID:[AB_439702](nif-antibody:AB_439702){#intref0020}anti-HPF1 (rabbit polyclonal)[@bib16]N/Aanti-Flag M2 agarose-conjugated (mouse monoclonal)Sigma-AldrichCat\#: A2220; RRID:[AB_1006303](nif-antibody:AB_1006303){#intref0025}anti-ARH3/ADPRH (rabbit polyclonal)Atlas AntibodiesCat\#: HPA027104; RRID:[AB_1060133](nif-antibody:AB_1060133){#intref0030}anti-histone H3, CT, pan (rabbit polyclonal)MilliporeCat\#: 07-690; RRID:[AB_417398](nif-antibody:AB_417398){#intref0035}anti-H3K9ac (rabbit monoclonal)Cell SignalingCat\#: 9649; RRID:[AB_823528](nif-antibody:AB_823528){#intref0040}anti-H3K14ac (rabbit monoclonal)Cell SignalingCat\#: 7627S; RRID:[AB_1083941](nif-antibody:AB_1083941){#intref0045}anti-H3K27ac (rabbit monoclonal)Cell SignalingCat\#: 8173P; RRID:[AB_1094988](nif-antibody:AB_1094988){#intref0050}anti-H3K36ac (rabbit monoclonal)Cell SignalingCat\#: 27683anti-H3K9me3 (rabbit polyclonal)AbcamCat\#: ab8898; RRID:[AB_306848](nif-antibody:AB_306848){#intref0055}anti-H3K27me3 (rabbit polyclonal)Gift from Rob Klose (University of Oxford)N/Aanti-pan-Kac (rabbit polyclonal)Cell SignalingCat\#: 9441; RRID:[AB_331805](nif-antibody:AB_331805){#intref0060}anti-H3S10P (rabbit polyclonal)AbcamCat\#: ab5176; RRID:[AB_304763](nif-antibody:AB_304763){#intref0065}anti-cyclin A (rabbit polyclonal)Santa Cruz BiotechnologyCat\#: sc-751; RRID:[AB_631329](nif-antibody:AB_631329){#intref0070}anti-cyclin B1 (rabbit polyclonal)MilliporeCat\#: 05-373; RRID:[AB_309701](nif-antibody:AB_309701){#intref0075}anti-cyclin E1 (mouse monoclonal)Cell SignalingCat\#: 4129; RRID:[AB_2071200](nif-antibody:AB_2071200){#intref0080}anti-PRC1 T481P (rabbit monoclonal)AbcamCat\#: ab62366; RRID:[AB_944969](nif-antibody:AB_944969){#intref0085}anti-Cdc2 Y15P (rabbit monoclonal)Cell SignalingCat\#: 4539S; RRID:[AB_560953](nif-antibody:AB_560953){#intref0090}anti-p21 (rabbit polyclonal)Santa Cruz BiotechnologyCat\#: sc-397; RRID:[AB_632126](nif-antibody:AB_632126){#intref0095}anti-pan-Kac (rabbit polyclonal)AbcamCat\#: ab21623; RRID:[AB_446436](nif-antibody:AB_446436){#intref0100}anti-PARP1 (rabbit monoclonal)AbcamCat\#: ab32138; RRID:[AB_777101](nif-antibody:AB_777101){#intref0105}**Experimental Models: Cell Lines**Human: U2OS cellsATCCCat\# HTB-96Human: U2OS ARH3 KO cells[@bib15]N/AHuman: 293T cellsATCCCat\# CRL-3216Human: 293T HPF1 KO cells[@bib16]N/AHuman: 293T PARP1 KO cellsGift from John Pascal (University Montreal)N/A**Recombinant DNA**pDONR221 (Gateway vector)Thermo Fisher Scientific12536017Flag-H3.1 WT (plasmid)[@bib41]N/AFlag-H3.1 S10A (plasmid)[@bib41]N/AFlag-H3.1 K9A (plasmid)This paperN/AFlag-H3.1 K9R (plasmid)This paperN/AFlag-H3.1 K9Q (plasmid)This paperN/AFlag-HPF1 WT (plasmid)[@bib16]N/AFlag-HPF1 Y238A (plasmid)[@bib16]N/AFlag-HPF1 Y238F (plasmid)This paperN/AFlag-HPF1 S97A (plasmid)This paperN/AFlag C3X-EV (Gateway vector)[@bib16]N/AFlag CMV-EV (Gateway vector)[@bib16]N/A**Software and Algorithms**MaxQuant proteomics suite of algorithms (version 1.5.3.17)[@bib9]<http://www.coxdocs.org/doku.php?id=maxquant:start>**Deposited Data**Mass spectrometry data: MS analysis of endogenous histones[@bib26]ProteomeXchange: [PXD005462](pride:PXD005462){#intref0115}Mass spectrometry data: enrichment of modified peptides with a macrodomain ADPr-binding module[@bib29]ProteomeXchange: [PXD004245](pride:PXD004245){#intref0120}Mass spectrometry data: cellular ADP-ribosylome characterization with HCD and EThcD[@bib4]ProteomeXchange: [PXD004676](pride:PXD004676){#intref0125}

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ivan Ahel (<ivan.ahel@path.ox.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Most of the experiments in these studies utilized recombinant protein and enzymes, as well as chemically synthesized peptides. For the cell biology experiments we used standard human model cell lines U2OS (ATCC HTB-96; osteosarcoma) and HEK293T (ATCC CRL-3216; embryonic kidney). The cells were grown in DMEM (Sigma-Aldrich) supplemented with 10% FBS (GIBCO) and penicillin-streptomycin (100 U/ml, GIBCO) at 37°C with 5% CO~2~. The generation of ARH3 KO U2OS cells was previously described ([@bib15]). Absence of mycoplasma contamination confirmed by MycoAlert Mycoplasma Detection Kit.

Methods Details {#sec4.4}
---------------

### *In vitro* ADPr assays {#sec4.4.1}

A variety of *in vitro* ADPr assays were used to measure the ability of enzymes to modify or demodify different substrates.

#### Recombinant proteins and peptides {#sec4.4.1.1}

Recombinant proteins are purified as described previously ([@bib21], [@bib22], [@bib16], [@bib15], [@bib13]). Peptides were purchased from EpiCypher or custom made. Nucleosomes were from EpiCypher.

#### Enzymatic preparation of the modified histone peptides {#sec4.4.1.2}

Recombinant Dim-5 (the homolog of human SUV39H1/2) and SIRT2 were purified as previously described ([@bib44], [@bib52]). Recombinant p300 was purchased from Enzo Life Sciences. HDAC2 was purchased from Active Motif. For histone phosphorylation reactions we used the activated Aurora B fragment called Baronase, which was a gift from the Barr lab ([@bib38]). H3 peptides were purchased from EpiCypher. H3 peptides (either WT or Ser-ADPr modified as described above) were incubated in either; HAT buffer (p300) - 50 mM Tris-HCl pH 8.0, 1mM DTT, 100 μM Acetyl-CoA, 10% glycerol for 30 min at 30°C; phosphorylation buffer (Baronase) - 50 mM Tris-HCl pH 7.5, 10 mM MgCl~2~, 1 mM ATP, 10 mM DTT for 60 min at 37°C; methyltransferase buffer (Dim-5,) -- 50mM Glycine pH 9.8, 2 mM DTT, 10% glycerol for 20 min at room temperature. Reactions were then analyzed by SDS-PAGE and western blotting (detailed below). HDACi reactions (HDAC2, SIRT2) were performed in reaction buffer contained 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 2 mM MgCl~2~, which were subsequently supplemented by PARP1/HPF1, activated DNA and 50 μM NAD^+^ spiked with ^32^PNAD^+^. The modification reaction proceeded at room temperature for 20 min before addition of the PARPi Olaparib at 1 μM. Reactions were then analyzed by SDS-PAGE and autoradiography.

#### Standard radioactivity-based ADPr assay {#sec4.4.1.3}

Recombinant proteins or peptides were ADPr by PARP1 in the presence or absence of HPF1 and histone peptides. PARP1 concentration in the assays was 1 μM unless stated otherwise, HPF1 was always equimolar to PARP1, histone peptides were used at 0.5 μg per reaction, and recombinant nucleosomes were at 1 μM. The PARP reaction buffer contained 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 2 mM MgCl~2~, activated DNA and 50 μM NAD^+^ spiked with ^32^PNAD^+^. The modification reaction proceeded at room temperature for 20 min before addition of the PARPi Olaparib at 1 μM. Reactions were then analyzed by SDS-PAGE and autoradiography.

#### Inverted polarity native gels for ADPr detection {#sec4.4.1.4}

This simple, non-radioactive method allows visualization of both substrates and products of ADPr reactions. ADPr reactions were performed as described above, except with 2 μg histone peptide per reaction, and in the presence of non-radioactive NAD^+^. Samples were mixed with TBE Sample Buffer and loaded on 20% TBE gels in TBE Running Buffer. Samples were run with inverted polarity at 200 V for 1 hr. Gels were then fixed for 30 min in 10% glutaraldehyde, washed in H~2~0 for 3 × 10 min, then stained with Imperial Protein Stain for 1 hr.

#### *In vitro* ADP-ribosyl glycohydrolase assays {#sec4.4.1.5}

The assays were performed as in Fontana et al., 2017. Briefly, H3 peptides were incubated with PARP1 and HPF1, under the conditions described above, and stopped by addition of Olaparib. ARH3 was then added to the reactions for incubation at room temperature for 30 min. Reactions were then analyzed by SDS-PAGE and autoradiography. ARH3 concentration was at 1 μM.

### Reanalysis of published high-quality proteomics datasets {#sec4.4.2}

For the reanalysis of published high-quality proteomics datasets, public raw files were analyzed with MaxQuant proteomics suite of algorithms (version 1.5.3.17) ([@bib9]), using the integrated search engine Andromeda ([@bib10]).

Data from the published proteomics study of peptides enriched with an ADPr-binding macrodomain ([@bib29]) were searched against the human proteome database (downloaded 09.10.2015 from UniProt) with the following parameters: the maximum allowed mass deviation was set to 4.5 ppm for precursor ions and 20 ppm for fragment ions; the minimum peptide length was set to 6 amino acids and the maximum number of missed cleavages was set to 5 with the maximum charge state 7. Variable modifications included acetylation (Protein N-term), Oxidation (M) and ADPr (DEKRSTCYNQHM). The variable modification ADPr allowed for neutral losses of adenine (m/z 136.0618); adenosine with loss of water (m/z 250.0935); AMP (m/z 348.0704); ADP (m/z 428.0367) and ADP-ribose (m/z 542.0684). FTMS top peaks per 100 Da were set to 20. We employed the annotated mass spectrometry (MS)/MS spectra generated by MaxQuant as the basis for our manual validation of spectra. To consider a peptide as modified on Tyr, we required the presence of fragment ions with either the intact ADP-ribose or phosphoribose (resulting from the loss of AMP) pointing to ADPr on Tyr. Unmodified "native" sequence ions were not considered as evidence for localization since it is impossible to distinguish between an original lack of modification and complete loss of ADPr during fragmentation. Two additional pieces of evidence supporting Tyr modification could also be observed in lower mass regions of these spectra. First, a peak matching the immonium ion of modified Tyr (+ ADPr -- AMPloss) could be observed (albeit weakly) in these spectra at 330.0742 Da (+1). The native (unmodified) Tyr immonium ion (136.0762) was also generally very weak (∼5%) in comparison to the immediately neighboring Adenine peak (136.0623) in these spectra, as opposed to those of peptides containing Tyr but with ADPR on serine. The significance of this ratio as support of Tyr modification can only be fully assessed with larger numbers of ETD-verified peptide spectra.

For the cellular ADPr characterization with HCD and EThcD study ([@bib4]), variable modifications included oxidation (M), acetylation (Protein N-term and K) and ADPr (DEKRSTYCMNQHM). For confident identification of ADPr sites, we considered only ETD MS/MS spectra and required a minimum Andromeda score of 100, mass deviation smaller than 3 ppm after MaxQuant recalibration and a localization score above 0.9. In addition, we manually validated all the representative spectra by requiring extensive coverage of the peptide backbone fragment ions. For localization we required the clear presence of multiple high-intensity fragment ions pinpointing the modification site.

For the cellular MS analysis of endogenous histones study ([@bib26]), variable modifications included oxidation (M), acetylation (Protein N-term and K), methylation (KR), dimethylation (K), trimethylation (K) and ADPr (DEKRSTYCMNQHM). Similarly, we considered only ETD MS/MS spectra and required a minimum Andromeda score of 100, mass deviation smaller than 3 ppm after MaxQuant recalibration and a localization score above 0.9.

### Western blotting {#sec4.4.3}

Human U2OS (ATCC HTB-96) and HEK293T (ATCC CRL-3216) cells were plated and grown overnight in DMEM (Sigma-Aldrich) supplemented with 10% FBS (GIBCO) and penicillin-streptomycin (100 U/ml, GIBCO). To induce DNA damage, cells were incubated with 2 mM H~2~O~2~ (Sigma-Aldrich) in DPBS with calcium and magnesium (GIBCO) for the indicated times. For PARPi, cells were pretreated with 10 μM Olaparib for 1 hr, and Olaparib was also added to the DPBS solution in case of the induction of DNA damage. Cells were lysed with Triton X-100 lysis buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 1% Triton X-100) at 4°C. Right before use, the buffer was supplemented with 5 mM MgCl~2~, protease and phosphatase inhibitors (Roche), 1 μM ADP-HPD and 1 μM Olaparib. Benzonase (Sigma) was added to the cell lysates and incubated for 20 min at 4°C. After centrifugation at 14,000 rpm for 15 min, supernatants were collected. Protein concentrations were analyzed by Bradford Protein Assay (Bio-Rad). Proteins were boiled in NuPAGE LDS sample buffer (Invitrogen), resolved on NuPAGE Novex 4%--12% Bis-Tris gels (Invitrogen), and transferred onto nitrocellulose membranes (Bio-Rad) using Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked in PBS buffer with 0.05% Tween 20 and 5% non-fat dried milk for 1 hr at room temperature, and incubated overnight with primary antibodies at 4°C, followed by 1-hour incubation with peroxidase-conjugated secondary antibodies at room temperature. Blots were developed using ECL (Invitrogen) and analyzed by exposing to films.

### Immunoprecipitation experiments {#sec4.4.4}

Flag-immunoprecipitation followed by western blotting was used to analyze the modification status of the precipitated proteins and their mutant versions. Full-length human histone H3.1 and HPF1 cDNAs were cloned into the pDONR221 vector (Thermo Fisher Scientific). Point mutations were produced in pDONR-H3.1 and pDONR-HPF1 using QuikChange Lightning site-directed mutagenesis kit (Agilent). Mammalian expression constructs expressed H3.1 proteins with the C-terminal 3xFlag tag, and HPF1 proteins with N-terminal Flag tag. Wild-type proteins and their mutant versions were expressed in 293T cells. The cells were plated, cultured overnight, and transfected using Polyfect (QIAGEN) with an empty vector or a plasmid expressing the Flag-tagged protein of interest for 24 hr essentially as described ([@bib41]). The cell lysates were obtained the same as for the western blotting. Protein concentrations were analyzed by Bradford Protein Assay (Bio-Rad), normalized, and then, the cell lysates were incubated with anti-Flag M2 agarose-conjugated mouse monoclonal antibody (Sigma-Aldrich) for 1 hr while rotating at 4°C. Beads were washed several times with Triton X-100 lysis buffer and eluted with NuPAGE LDS sample buffer (Invitrogen). The samples were then analyzed by Western Blotting as described above.
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The qualitative gel-based assays were used to visualize the experimental results. Representative gels from at least three independent biological replicates were shown.
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